Embarking on a temporal voyage, Hong Kong's Chinese Herbal Medicine Drug Development Center champions the progressive evolution from herbal medicine to modern prescription drugs, bridging the gap between ancient healing practices and the demands of contemporary healthcare.

Napo Pharmaceuticals's pivotal phase 3 OnTarget trial for prophylaxis of diarrhea in adult cancer patients is a 12-week trial targets cancer therapy-related diarrhea. The product emphasizes ethical and sustainable practices and bring new hope in CIOB management by prioritizing patient well-being.

NexoBrid is a topical gel that removes dead tissue, called eschar, from burns. It's made from proteolytic enzymes enriched in bromelain from pineapple stems. NexoBrid is used to treat adults with deep partial thickness and full thickness thermal burns.

Coacillium, Legacy Healthcare's plant-based remedy, shows promise for alopecia areata, fostering hair regrowth in children per 2023 EADV research. Notably, it sustains remission without immune-altering effects, marking a breakthrough in dermatological care.

Abstract: botanical drug clinical trials registered at ClinicalTrial.gov were analyzed. Trends in current trials were discovered and guide future trials was recommended. A total of 195 botanical drug clinical trials were registered from 2016 to 2019, of which 81 are phase II or phase II/III. Most were with 100 or less participants per arm ...

In patients with ST-segment elevation myocardial infarction (STEMI), the traditional Chinese medicine Tongxinluo, as an adjunctive therapy to guideline-directed treatment, is associated with significantly improved clinical outcomes, according to a study published in the Oct issue of the J of the American Medical Association.

Alphyn Biologics, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics, released interim results today from the second cohort of its Phase 2a clinical trial program of AB-101a, a novel topical candidate for atopic dermatitis (AD).

Hong Kong Baptist University is set to conduct the first phase of clinical trials for a novel Chinese medicine targeting chronic constipation in the US, after it gained the US FDA approval to proceed. The medicine, known as CDD-2101, represents a significant milestone as the first botanical drug developed in Hong Kong.

A University team of researchers have discovered that extracts from plants used by the First Nations peoples in their traditional botanical medicine practices are able to rescue the function of ion channel proteins carrying mutations that cause human Episodic Ataxia.

Sinoveda is a health brand that is bringing innovative, herbally-based precision to drug discovery, created a patented pharmaceutical platform technology (PPT) used to study herbs with a historical record of efficacy.

A showcase of the first botanical drug approved by the US FDA for treating diarrheal caused by HIV/AIDS antiretroviral therapy, about the what was described for the structure, methods to test and ensure therapeutic consistency, studies of dose response. This set an example for future botanical drug development.

Napo Pharmaceuticals Inc announced the submission of an IND application to the U.S. FDA for a new crofelemer powder for oral solution formulation for the treatment of microvillus inclusion disease (MVID).

RS BioTherapeutics received $3M capital from its second seed round to focus on developing a medication for chronic obstructive pulmonary disease

ReHeva Biosciences is announcing the first patient enrolled and dosed in the Phase I Safety Trial for the company's drug, RH324.

Abstract: anti‑inflammatory therapies and vaccine approach are not effective in treating viruses. A multi‑target approach has been used with success for human immunodeficiency virus and some types of cancer. It has been recently proposed to use the same strategy for COVID‑19.

The United States FDA has received over 800 botanical investigational new drug applications (IND) and pre-IND meeting requests (PIND) in the years preceding 2018. Between 2016 and 2019, 195 botanical drug clinical trials were registered, of which 81 are phase 2. By the end of 2018, over 600 IND applications were in clinical development under the botanical drug category.

The new strain of yeast probiotic developed by a yeast company in China, S. boulardii Bld-3, is ground-breaking addition to the S. boulardii family that has been proven effective in speeding up recovery from acute diarrhea and is beneficial to intestinal health in the long term

Yiviva, a pharmaceutical company focused on developing botanical drugs, has moved its lead candidate further into an international phase IIb trial for liver cancer and closer to an application through the FDA’s little-used botanicals pathway and a similar pathway in China.

The U.S. Food and Drug Administration (FDA) gave priority review to Amryt Pharma’s application seeking approval of Filsuvez (Oleogel-S10), a topical gel to treat skin wounds in people epidermolysis bullosa (EB).

Treatment with 0.5 mol/L acetic acid can stimulate the degradation of polar ginsenosides to less polar ginsenosides (5.6% Rg3 was accumulated, P < 0.0001).

Helixmith said it has begun the clinical trials of its natural extract-based Covid-19 drug TADIOS (HX110) with infected patients in India by giving its first dose on Thursday.

Abstract
Huajuhong (Exocarpium Citri grandis, ECG) is a traditional Chinese herbal medicine and has been used for the treatment of respiratory diseases for hundreds of years. Recently, ...

Abstract: Among all the compounds, chlorogenic acid showed druggable characteristics and scored the lowest binding energy with main protease and main peptidase via interacting with active site 1 domain amino acid residues. Interestingly, chlorogenic acid interacted with Phe140 main protease 3CLpro, which is potentially involved in the dimerization.

The 11th revision of the World Health Organization’s (WHO) International Statistical Classification of Diseases and Related Health Problems (ICD) includes Traditional Chinese Medicine (TCM) for the first time, and will come into effect on January 1, 2022.

ABSTRACT: Network pharmacology and polypharmacology are emerging as novel drug discovery paradigms. The many discovery, safety and regulatory issues they raise may become tractable with polypharmacological combinations of natural compounds found in whole extracts of edible and mixes thereof.

In a UCLA-led phase I clinical trial, a new plant-based drug called APG-157 showed signs of helping patients fight oral and oropharyngeal cancers. These cancers are located in the head and the neck.

The Council for Scientific and Industrial Research (CSIR) has received approval from Drug Controller General of India (DGCI) for its two clinical trial drugs - 'favipiravir' and 'phytopharmaceutical' - to combat coronavirus.

The first patients have been dosed in a multi-regional Phase IIB randomized, placebo-controlled clinical trial for the treatment of hepatitis B-associated liver cancer.

Cancer is one of the largest causes of morbimortality in the world and due to its prevalence the discovery of novel anticancer drugs in of great importance. The past century brought great advances in the field of plant and microbiology research, with the ......

ABSTRACT: Botanical drug products have batch-to-batch quality variability due to botanical raw materials and the current manufacturing process. The rational evaluation and control of product quality consistency are essential to ensure the efficacy and safety. Chromatographic fingerprinting is an ...

ABSTRACT: Quality control plays a critical role in the process of translating the traditional/alternative medicines into modern evidence-based therapies. High performance liquid chromatography (HPLC) is widely ...

As in drug discovery and development, mass spectrometry has become essential at all stages for establishing the safety and efficacy of botanical dietary supplements. Applications of mass spectrometry to the development ...

Development of botanical drug products in the U.S. may be entitled for a waiver of preclinical Pharm/Tox (P/T) studies prior to an initial clinical trial, contingent upon existing previous human experience.

Traditional Chinese Medicines (TCM) are rapidly gaining attention in the West as sources of new drugs, dietary supplements and functional foods. However, ...

Recently, chromatographic fingerprinting has become one of the most powerful approaches to quality control of herbal medicines. However, the performance of reported chromatographic fingerprinting constructed by single chromatogram sometimes turns out to be inadequate for complex herbal medicines, ...

Regulatory pathways and characteristic quality requirements for marketing authorization of herbal medicinal products in the European Union（EU), and the legal status and applications of "European Union list of herbal substances, preparations and combinations" and "European Union herbal monographs".

In 2015 a draft Guidance for Industry: Botanical Drug Development. The draft revised botanical guidance provides additional recommendations on quality, nonclinical, clinical, and other unique aspects associated botanical drug development.

History and evaluation of developing medicines from plants

Canada’s Tetra Bio-Pharma is on a path to become a world leader in the development of cannabinoid-derived medicines, with several promising drugs undergoing advanced clinical trials.

Israeli researchers have succeeded in destroying breast cancer cells after developing a new treatment that "combines the application of low-frequency ultrasound and microbubbles," Tel Aviv University's Department of Biomedical Engineering announced on Thursday.

Now, in a landmark moment in cancer research, Cheng and research partners are launching the first international clinical trial for a botanical drug, YIV-906. The trial, involving patients with liver cancer and hepatitis B, will take place at 20 institutions across the United States, China, Taiwan, and Hong Kong. Lead sites include Memorial Sloan Kettering and Northwell Health Cancer ...

Pfizer, Eli Lilly, Novo Nordisk, Boehringer Ingelheim, Bayer Pharmaceuticals, Merck are teaming up to create an initial $1 billion for-profit venture to bet on small biotechs developing mid-stage antibiotics.

(cannabidiol) [CBD] oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older.

Israeli pharma-tech company, Syqe Medical, set out to test a first-of-its-kind product that reportedly enables precise dosing of low-levels of THC to control pain.

An Ivestigational New Drug Application (IND) for the use of FSD201 (ultramicronized palm itoylethanolamide, or ultramicronized PEA) to treat COVID-19, the disease caused by the SARS-CoV-2 virus (the "FSD201 COVID-19 Trial") was announced by FSD Pharma Inc.

Research published Friday in a journal, "JAMA Cardiology", found that 4 out of 26 college athletes had signs of a heart condition called myocarditis after recovering from COVID-19.

The US Food and Drug Administration has approved remdesivir for the treatment of coronavirus infection, the drug's maker, Gilead Sciences.

By the end of Oct 2020, FDA issued 123 first-time warning letters this year to dietary supplement companies regarding unapproved and misbranded products related to covid19. Those products are herbal products and hemp products marketed online and on social media networks.

University of Houston professor of pharmaceutics Ming Hu is developing and testing an ancient Chinese herbal medicine formula, first described in 280 A.D., to improve cancer therapy.

California-based GW said it will launch the first Phase III trial studying nabiximols, which is known as Sativex outside the United States, as a potential treatment for multiple sclerosis-associated spasticity.

The U.S. Federal Trade Commission announced its first crackdown on deceptive claims in the CBD market Thursday, issuing fines and sanctions to six manufacturers accused of misleading consumers about the health benefits of the cannabis extract.

DA approved the IND application to proceed with initiation of a Phase 2 clinical trial of Brilacidin in hospitalized patients with COVID-19.